Background {#Sec1}
==========

Type 2 diabetes mellitus (T2DM) is characterized by prolonged systemic insulin resistance, resultant impaired insulin insufficiency, and life-threatening micro- and macro-vascular complications \[[@CR1]--[@CR4]\]. The risk of cardiovascular (CV) disease is already increased in the pre-diabetic state of impaired glucose tolerance (IGT) and is associated to a greater degree with impaired fasting and/or 2-h plasma glucose than with HbA1c levels \[[@CR5]--[@CR8]\]. Abnormal glycemic metabolism therefore has a central role in diabetic pathophysiology. However, whether glucose-lowering treatments reduce the risk of future CV events still remains controversial, despite the legacy-effect of long-term intensive glycemic intervention \[[@CR9]--[@CR11]\]. Given the multi-factorial nature of T2DM progression, early medical intervention using a comprehensive approach according to an individual's medical background needs to be emphasized in the management of the disorders \[[@CR12], [@CR13]\]. However, relevant risk factors are often not controlled optimally, and no conventional anti-diabetic agents can easily achieve such therapeutic goals. Given the worldwide increase in the number of patients with the metabolic syndrome including obesity and diabetes \[[@CR14], [@CR15]\], early establishment of therapeutic strategies to prevent the subsequent occurrence of obesity/diabetes-related CV complications is urgently required.

Sodium glucose cotransporter 2 (SGLT2) inhibitors are novel glucose-lowering agents that increase urinary glucose excretion by modulating selective inhibition of SGLT2 in the proximal renal tubule \[[@CR16]\]. SGLT2 inhibitors alleviate glucotoxicity in an insulin-independent manner and improve beta-cell dysfunction, and therefore may have indirect metabolic benefits \[[@CR17]\]. Of the SGLT2 inhibitors, ipragliflozin was developed in Japan. There is evidence that ipragliflozin has the favorable metabolic effects, including improved glycemic control, and decreased blood pressure (BP), body weight (BW), and visceral adipose tissue, indicating a potential CV protective effect \[[@CR18], [@CR19]\]. Several mega-clinical trials designed to clarify the effects of SGLT2 inhibitors on clinical CV outcomes are now in progress \[[@CR20]\]. Of these trials, EMPA-REG OUTCOME trial showed that empagliflozin markedly reduced the risk of CV mortality compared to placebo \[[@CR21]\]. Although CV mortality and worsening of heart failure were both decreased dramatically, empagliflozin treatment failed to reduce macro-vascular events, such as non-fatal myocardial infarction and stroke. The clinical impact of SGLT2 inhibitors on CV benefits has therefore attracted considerable attention, although the mechanisms by which SGLT2 inhibitors exert these benefits beyond glucose-lowering are not fully understood. In particular, clinical evidence regarding the therapeutic effect of SGLT2 inhibitors on arteriosclerosis in patients with diabetes is still lacking. The effects on arteriosclerosis of other anti-diabetic agents, such as pioglitazone and dipeptidyl peptidase 4 (DPP-4) inhibitors, have been evaluated in randomized clinical trials using surrogate markers, such as carotid intima-media thickness (IMT) \[[@CR22]--[@CR25]\]. This method is well-established and has good reproducibility and reliability to reflect the clinical severity of systemic atherosclerosis, and is therefore useful for evaluating drug efficacy.

On the basis of this background, the PROTECT study was designed to evaluate the anti-atherosclerotic effect of ipragliflozin using IMT as a surrogate marker for the risk of CV events and also to clarify the mechanisms by which SGLT2 inhibitors may improve CV outcomes. This study may provide novel evidence regarding SGLT2 inhibitor-mediated pharmacological intervention on carotid atherosclerosis.

Methods {#Sec2}
=======

Study overview and design {#Sec3}
-------------------------

The PROTECT study is an ongoing, multicenter, prospective, randomized, open-label, blinded-endpoint, parallel group, investigator-initiated clinical trial (phase IV). The study will test the hypothesis that compared to standard care alone, the addition of ipragliflozin to standard care in T2DM may suppress the progression of carotid atherosclerosis, accompanied by an improvement in glycemic and lipid metabolism and vascular function. After recruitment and randomization of the patients into groups with or without ipragliflozin, each treatment is continued for 24 months, and the long-term safety and effects of ipragliflozin on CV systems then evaluated.

The study protocol was approved by the local institutional review boards and independent ethics committees. The study will be conducted in full compliance with the articles of the Declaration of Helsinki and according to the Ethical Guidelines for Medical and Health Research Involving Human Subjects established by the Ministry of Health, Labour, and Welfare and Ministry of Education, Culture, Sports, Science, and Technology. The PROTECT study was registered by the UMIN in July 2015 (ID: 000018440).

Study population and recruitment {#Sec4}
--------------------------------

We aim to recruit a total of 480 participants across approximately 35 sites in Japan. Recruitment for the study began in September 2015 and will end in December 2017. Eligible participants for the study are T2DM patients who comply with all the enrollment criteria. The detailed inclusion and exclusion criteria are listed in Table [1](#Tab1){ref-type="table"}. Briefly, patients will be enrolled if they are aged ≥20 year, diagnosed as having T2DM in accordance with the Japanese guidelines \[[@CR26]\], with a HbA1c between 6.0 and 10.0 % despite diet and exercise therapy and/or taking standard medications for at least 3 months prior to randomization. After initial screening using previous medical records, each participant is required to receive an adequate explanation of the study plan, with written informed consent then being obtained.Table 1Detailed inclusion and exclusion criteriaInclusionExclusionAdults (aged ≥20 years)Type 1 diabetes mellitusT2DM with 6.0 % ≤ HbA1c \< 10.0 % despite diet and exercise therapy and/or the standard medications for at least 3 months prior to randomizationHistory of severe ketosis, diabetic coma, orThe patient provided written informed consent to participate in the studyPrecoma attack ≤6 months prior to informed consentPatients with severe infection or trauma at trial screeningPatients in perioperative period around trial screeningSevere renal dysfunction (eGFR **\<** 45 ml/min/1.73 m^2^) or patients receiving dialysisHistory of coronary artery disease, coronary vascularization, open-heart surgery, stroke, or transient ischemic attack ≤3 months prior to eligibilityCHF (NYHA functional classification III and IV)History of administration of SGLT2 inhibitor 1 month prior to study initiationPregnant or suspected pregnancy in femalesLactating femaleHistory of hypersensitivity to ingredients of ipragliflozinConsidered inappropriate for the study by investigators due to other reasons, such as malignancy*CHF* chronic heart failure, *eGFR* estimated glomerular filtration rate, *NYHA* New York Heart Association, *SGLT2* sodium glucose cotransporter 2, *T2DM* type 2 diabetes mellitus

Study outline and follow up {#Sec5}
---------------------------

After informed consent has been obtained and the eligibility assessment is completed, all eligible participants will be randomized and assigned into either the ipragliflozin group or standard-care (control) group. Follow-up visits are scheduled at 3, 6, 12 and 24 months (Fig. [1](#Fig1){ref-type="fig"}). All participants will see their usual-care physicians at each visit to receive usual-care and individualized appropriate treatment according to their background disease, in addition to administration of the study drug.Fig. 1Study outline

Randomization and treatment {#Sec6}
---------------------------

Eligible participants with appropriately signed informed consent will be randomized to either the ipragliflozin group or control group (ratio 1:1) using the web-based minimization method with biased coin assignment balancing \[[@CR27], [@CR28]\] for age (\<65, ≥65 year), HbA1c level (\<7.0, ≥7.0 %), systolic BP (\<135, ≥135 mmHg), use of statins, and use of biguanides at the time of screening.

All participants will be followed-up for 24 months. Although a specific numerical goal in glycemic control such as HbA1c level is not set for the study, all participants need to be treated to achieve a personalized goal recommended by the treatment guideline in Japan (details in Additional file [1](#MOESM1){ref-type="media"}) \[[@CR26]\]. Participants who are assigned to the ipragliflozin group receive ipragliflozin 50 mg once daily in addition to their background medical therapy. In accordance with official recommendation regarding use of SGLT2 inhibitor from the Japan Diabetes Society \[[@CR29]\], patients aged ≥75 years should be most carefully followed up with particular attention to development of volume depletion-related adverse drug reactions \[[@CR30]\]. If the personalized goal is not achieved, the dose of ipragliflozin can be increased by the investigators to 100 mg once daily. Participants who are assigned to the control group continue their background therapy. Within the appropriate range of the therapeutic goal, the participant's background therapy will be, in principle and if possible, unchanged during the study in both groups. However, if participants cannot achieve their glycemic goal, co-administration of anti-diabetic agents other than SGLT2 inhibitors or increased dosages of the other anti-diabetic agents in both groups may be considered by investigators, with caution being taken to prevent the development of hypoglycemia. However, because pioglitazone is known to have a suppressive effect on the progression of IMT, compared to glimepiride \[[@CR22]\], it is prohibited to prescribe it or change its dose during the study. After the study is completed, all participants can continue any anti-diabetic treatment in accordance with their individual condition.

Measurements {#Sec7}
------------

Baseline characteristics, including gender, age, body height and weight, abdominal circumference, complications, duration of T2DM, background treatment, and smoking and drinking habits will be recorded prior to randomization. The status of the study medications and the participant's background treatment will be recorded at each visit. Measurements of BP, pulse rate, BW, and body mass index (BMI) will also be carried out at baseline and after 12 and 24 months. Abdominal circumference will be measured at baseline and 24 months. Blood tests without HbA1c level will be checked at baseline and 24 months (details listed in Additional file [2](#MOESM2){ref-type="media"}); HbA1c will be measured at baseline and after 12 and 24 months. Specific biomarkers such as N-terminal pro-brain natriuretic peptide (NT-proBNP), high-sensitivity C reactive protein (hsCRP), high-molecular weight adiponectin, and malondialdehyde modified low-density lipoprotein (MDA-LDL) will be measured at baseline and 24 months. Creatinine-corrected urinary albumin excretion will be measured at baseline and 24 months (optional). Some optional imaging and physiological tests are also planned in the study including abdominal computed tomography to measure the amount of visceral and subcutaneous fat, echocardiograms, flow-mediated dilation (FMD), pulse-wave velocity (PWV), cardio-ankle vascular index (CAVI), and augmentation index (AI) (details listed in Additional file [3](#MOESM3){ref-type="media"}).

### Measurement of carotid IMT {#Sec8}

The protocol and method for measuring carotid IMT have been described in detail previously \[[@CR25], [@CR31], [@CR32]\]. In brief, the carotid ultrasound examinations using standardized imaging protocols and systems equipped with \>7.5 MHz linear transducers will be performed at each local site and then measured at a core laboratory (Tsukuba University) at baseline and 24 months after randomization. Expert trained sonographers who have attended a lecture on measuring carotid IMT will carry out the procedure according to the Mannheim carotid IMT consensus \[[@CR33], [@CR34]\]. The head position and probe angle of the ultrasound approach will be set using a ruler located just cephalad (Fig. [2](#Fig2){ref-type="fig"}). Longitudinal B-mode images, perpendicular to the ultrasound beam, with a 3--4 cm imaging depth, will be recorded in the distal common carotid arteries (CCA), carotid bulbs, and proximal internal carotid arteries (ICA) on both sides. The lateral probe incidence is used to obtain CCA images, using external landmarks and an original semicircular protractor developed for this purpose. The mean CCA-IMT indicates the average IMT value of the right and left CCA-IMT, 10 mm from the bulb. The following far wall IMTs will be measured; maximum IMT of the CCA and mean and maximum IMTs of the bulb and ICA. The optimized R-wave gated still frames of the carotid IMT will be stored as JPEG files, with all the parameters collected and measured at the core laboratory. An expert analyzer blinded to the allocation and clinical information of the subjects will measure all the IMT values using an automatic IMT measurement software program (Vascular Research Tools 5, Medical Imaging Applications, Iowa, USA) \[[@CR35]\]. The software program identifies the lumen/intima and the media/adventitia borders in this region and calculates the distance between them.Fig. 2Method for measuring IMT. **a** Head position is set at 45° toward the other side (*right*) when measuring at the left carotid artery. **b** The probe angle is also set at 45° using the ruler on the test side. **c** A plus B. **d** Schema for measuring the left carotid artery. The probe is set perpendicular to the sagittal plane

Safety {#Sec9}
------

Based on the intention-to-treat the entire population, safety will be checked by recording the following adverse effects (AEs) throughout the study: severe AEs regardless as to whether or not there is causal relationship between the AEs and the study; and relevant AEs such as hypoglycemia, genital or urinary tract infections, ketoacidosis, and hypovolemic symptoms. When the investigators confirm these AEs, the grade of severity, procedures, outcomes, and relationship to the study drug will be assessed. A prompt report to the study secretariat and to the Data and Safety Monitoring Board (DSMB) will then be made by the trial organizer. The members of the DSMB consist of authorized endocrinologists, cardiologists, or neurologist with relevant expertise. The criteria for withdrawal from the trial are listed in Table [2](#Tab2){ref-type="table"}. The incident of withdrawal from the study will be reported promptly to the DSMB by the chief investigator. The DSMB will then deliberate on the incident and report the decision to the chief investigator.Table 2Discontinuance criteriaSevere hypoglycemiaSeriously poor glycemic control such as ≥HbA1c 12.0 % confirmed by second measurement on different dayOffer for participation declined by participantsDeviancy of eligibility after registrationConsidered inappropriate to continue the study by investigators due to aggravation of primary disease or complicationsConsidered inappropriate to continue the study by investigators due to adverse side effects of the study drugPregnantPoor drug adherence (\<75 %, or \>120 %)Considered inappropriate to continue the study by investigators due to some other reason

Study endpoints {#Sec10}
---------------

Intima-media thickness (IMT) in the carotid artery is well-established as a surrogate marker for risk of CV diseases and is also useful for evaluating the effectiveness of various types of therapeutic interventions in patients with or without T2DM \[[@CR35]--[@CR37]\]. The primary endpoint in the study is the change in mean IMT of the CCA from baseline to 24 months. The secondary endpoints are the values and changes in parameters after 24 months of treatment, including: (1) mean IMT of the bulb and ICA, (2) max IMT of the CCA, bulb, and ICA, (3) the overall mean of mean IMT of the CCA, bulb, and ICA, (4) the mean of max IMT of the CCA, bulb, and ICA, (5) specific biomarkers including hsCRP, MDA-LDL, NT-proBNP, and high-molecular weight adiponectin, (6) the cardiovascular functional tests listed in Additional file [3](#MOESM3){ref-type="media"} (optional), (7) abdominal circumference and amount of visceral and subcutaneous fat measured by abdominal computed tomography (optional), (8) creatinine-corrected urinary albumin excretion. In addition, the values and changes after 12 and 24 months in several clinical parameters including BP, BW, and BMI and laboratory data (details listed in Additional file [2](#MOESM2){ref-type="media"}) will be evaluated. Safety endpoints also include AEs and adverse drug reactions observed during the study.

Statistical considerations {#Sec11}
--------------------------

### Sample size estimation {#Sec12}

Due to the lack of data on the effect of SGLT2 inhibitors on carotid IMT, we referred to the statistical data from the CHICAGO study \[[@CR22]\] and PROLOGUE study \[[@CR25]\]. In the CHICAGO study, pioglitazone caused a significant inhibition of the progression of CCA-IMT (−0.0010 mm after 72 weeks), compared to glimepiride (+0.0120 mm after 72 weeks). We estimated the changes from baseline would be −0.0013 mm (pioglitazone) and +0.016 mm (glimepiride) after 96 weeks. Based on the assumption that ipragliflozin may inhibit the progression of CCA-IMT to the same extent as pioglitazone, we estimated the group difference as 0.016 (ipragliflozin −0.001 and control +0.015) ±0.06 (standard deviation). At a significant level of 5 % (two-sided), the sample size of 222 patients per arm provides a power of 80 % for each comparison. Allowing for a dropout rate of 5 %, 240 patients in each arm (a total of 480 patients) provides sufficient statistical power for the study.

### Statistical analysis plan {#Sec13}

The analyses of the primary and secondary endpoints will be performed in the full analysis set (FAS), which includes all participants who received at least one dose of treatment during the study period and did not have any serious violation of the study protocol such as not providing informed consent, registration outside of the study period, or data collected after commencement of treatment.

Summary statistics will be calculated for the baseline characteristics including the frequencies and proportions for categorical variables and means ± standard deviations for continuous variables. The patient characteristics will be compared using Chi square tests for categorical variables, t tests for normally distributed continuous variables, or the Wilcoxon rank sum tests for continuous variables with a skewed distribution.

The analysis plan is similar to that used in previous studies we have conducted \[[@CR25], [@CR31], [@CR32]\]. In brief, for the primary analysis comparing treatment effects, the baseline-adjusted means and their 95 % confidence intervals, estimated by analysis of covariance of the change in average carotid IMT at 24 months, will be compared between the treatment groups (ipragliflozin group vs. control group). The results will be adjusted by allocation factors. The primary analysis will not include missing observations, with the mixed effects model for repeated measures (MMRM) being used as a sensitivity analysis to examine the effect of missing data. In addition, MMRM will be used as a sensitivity analysis to examine the outcomes at baseline and 24 months modelled as a function of time, treatment, and treatment-by-time interaction. The secondary analysis will be performed in the same manner as the primary analysis.

All comparisons are planned and all *P* values will be two sided. *P* values \<0.05 will be considered statistically significant. All statistical analyses will be performed using SAS software version 9.4 (SAS Institute, Cary, NC, USA). The statistical analysis plan will be developed by the principal investigator and a biostatistician before completion of patient recruitment and database lock.

Study organization and oversight {#Sec14}
--------------------------------

The principal investigators of the PROTECT study are (details in Additional file [4](#MOESM4){ref-type="media"}) Koichi Node (Chief), Department of Cardiovascular Medicine, Saga University and Toyoaki Murohara, Department of Cardiology, Nagoya University Graduate School of Medicine. The research advisor is Masafumi Kitakaze, Department of Clinical Medicine and Development, National Cerebral and Cardiovascular Center. The steering committee will carry out planning, operating, analyzing, and presentation of the trial. The executive committee will supervise the trial design and operation of the study. The roles of the DSMB are described in the section on Safety. The trial secretariat is in DOT INTERNATIONAL CO., LTD, Tokyo, Japan. Each data management, monitoring, statistical analyses, and audit will be implemented independently on the basis of the outsourcing agreement. Carotid IMT will be measured at a core laboratory, Tsukuba University. Data monitoring will be enforced to ensure the research is performed properly, with an independent audit team inspecting several main institutes to ensure the quality of the study data.

Discussion {#Sec15}
==========

The PROTECT study is an ongoing, multicenter, prospective, randomized, investigator-initiated clinical trial that has the aim of assessing the add-on effect of ipragliflozin using carotid IMT as a surrogate marker of CV risk. Cardiac and vascular functional tests will also be evaluated as secondary endpoints. Eligible patients with T2DM will be assigned to ipragliflozin or conventional standard care groups. The primary endpoint is the change in mean IMT of the CCA from baseline to 24 months of treatment. The study has the potential to provide novel clinical evidence on the anti-atherosclerotic effect of ipragliflozin.

Carotid IMT is used widely as a noninvasive measure of systemic atherosclerotic state and to predict subsequent CV events and mortality \[[@CR38], [@CR39]\]. A number of studies have demonstrated that increased IMT correlates strongly with the risk of future CV disease in a wide range of populations, especially T2DM patients \[[@CR40]--[@CR44]\]. Measuring carotid IMT is also recognized as a useful surrogate marker for evaluating the efficacy of therapeutic interventions on CV risk factors and atherosclerotic diseases \[[@CR37], [@CR45]--[@CR47]\]. Although the current study is a multicenter open-label design, repeated IMT measurements are planned in a blinded manner. The analyses will be carried out at a core laboratory according to global recommendations in order to avoid bias and measurement error between institutions \[[@CR48]\]. The same systematic procedures for analysis of carotid IMT were used in our previous and other ongoing studies \[[@CR25], [@CR31], [@CR32]\]. The reliability and reproducibility of measurements of carotid IMT will be highly certified in the current study.

Because diabetes contributes strongly to accelerated progression of carotid IMT \[[@CR49]\], the inhibitory effects of several anti-diabetic agents on carotid IMT progression have been investigated extensively. In the CHICAGO study \[[@CR22]\], mean and max carotid IMT progression was significantly lower in the pioglitazone group compared to the glimepiride group. This inhibitory effect has been confirmed in other clinical trials \[[@CR50]\] and is, in part, consistent with the result from a large-scale outcome study, the Prospective Pioglitazone Clinical Trial in Macrovascular Events (PROactive). That study demonstrated that the addition of pioglitazone was associated with a 16 % risk reduction in the composite of all-cause mortality and non-fatal macro-vascular events compared to the addition of placebo \[[@CR51]\]. Even in the IGT subjects, acarbose, an alpha-glucosidase inhibitor, also attenuated significantly the mean IMT progression relative to placebo \[[@CR52]\]. This result may provide a possible mechanism by which acarbose reduced the incidence of cardiovascular events in the earlier trial \[[@CR53]\]. Regarding DPP-4 inhibitors, the TECOS trial that evaluated CV outcomes in 14,671 T2DM patients with established CV disease showed a neutral effect of sitagliptin on the risk of major adverse CV events during a median follow-up of 3 years \[[@CR54]\]. The other outcome mega-trials that evaluated CV safety of DPP-4 inhibitors, the EXAMINE and SAVOR-TIMI 53 studies, also showed similar results \[[@CR55], [@CR56]\]. Interestingly, in the Program of Vascular Evaluation under Glucose Control by a DPP-4 Inhibitor (PROLOGUE), sitagliptin failed to inhibit the progression of carotid IMT compared to standard diabetes care during 24 months of follow-up \[[@CR25]\]. In contrast, other studies of DPP-4 inhibitors have demonstrated a beneficial effect on progression of carotid IMT \[[@CR23], [@CR24]\]. The reasons for this discrepancy remain uncertain, although clinical differences in the patients' background, such as concomitant drugs and severity of diabetes and CV risk may, in part, influence the effectiveness of DPP-4 inhibitors on carotid atherosclerosis. Recent clinical trials also clearly show a close association between anti-diabetic agents-mediated changes in carotid IMT and CV outcomes in the majority of T2DM patients.

SGLT2 inhibitors are a novel class of oral anti-diabetic agent that lower blood glucose level by increasing urinary glucose excretion. In addition to the glycemic pathway, SGLT2 inhibitors are associated closely with non-glycemic modifications, such as hemodynamic, metabolic, renal, and neurohormonal effects \[[@CR20], [@CR57]\]. In 2015, the EMPA-REG OUTCOME trial reported outstanding results that the SGLT2 inhibitor, empagliflozin, markedly improved clinical outcomes in diabetes patients with a higher CV risk \[[@CR21]\]. Because other outcome trials using SGLT2 inhibitors other than empagliflozin are now ongoing \[[@CR58]--[@CR60]\], it still remains to be determined whether this clinical impact is a class effect of SGLT2 inhibitors. However, given their mode of action and favorable effects on the entire CV system, it is very likely that further positive evidence may be obtained \[[@CR61]\]. In the EMPA-REG OUTCOME trial, empagliflozin caused a significant reduction in CV mortality and hospitalization for worsened heart failure rather than macrovascular complications, such as non-fatal myocardial infarction and stroke. Based on these beneficial clinical outcomes, possible mechanisms may be largely hemodynamic effects induced by glycosuria and natriuresis, rather than a direct anti-atherothrombotic effect \[[@CR62]--[@CR64]\]. However, SGLT2 inhibitors ameliorate various risk factors related to CV disease, such as BP, BW, uric acid, and lipid profiles independent of glycemic control per sé, suggesting the possible existence of anti-atherosclerotic actions. Indeed, there is evidence that SGLT2 inhibitors prevent excess oxidative stress and inflammation in animal models \[[@CR65]--[@CR69]\]. In clinical studies, direct effects on arterial stiffness were also observed in patients with type 1and type 2 diabetes \[[@CR70], [@CR71]\]. Although the increased incidence of non-fatal stroke was reported in the EMPA-REG OUTCOME trial and subsequent meta-analyses \[[@CR21], [@CR61]\], the study duration may have been too short to prevent the occurrence of atherogenic macro-vascular events, including stroke. Importantly, the precise effects of SGLT2 inhibitor on local and systemic atherosclerosis in clinical settings have proved elusive. It would therefore be plausible to implement a mechanistic study using a surrogate marker as a study endpoint.

In the current study, we are attempting to assess the preventive effect of a SGLT2 inhibitor, ipragliflozin, on carotid IMT progression. In 2014, ipragliflozin was the first SGLT2 inhibitor to be released in Japan \[[@CR19]\]. Tahara et al. \[[@CR72]\] reported that compared to other SGLT2 inhibitors, ipragliflozin had a relatively longer-acting and earlier-onset of action on renal SGLT2. Accumulated evidence from the initial clinical studies in Japanese T2DM patients also showed short- and long-term favorable effects of ipragliflozin on glycemic, metabolic, and safety parameters \[[@CR30], [@CR73]--[@CR77]\]. Takahara et al. \[[@CR78]\] also reported that ipragliflozin treatment improved pancreatic beta-cell dysfunction and subsequent insulin resistance in T2DM patients, similar to that reported for other SGLT2 inhibitors \[[@CR79], [@CR80]\]. Systemic insulin resistance (IR) plays a pivotal role in the pathogenesis and progression of obesity and noninsulin-dependent diabetes mellitus \[[@CR81]\]. It is also known that insulin resistance and resultant diabetes are associated closely with non-alcoholic fatty liver disease (NAFLD), including non-alcoholic steatohepatitis (NASH); a progressive phenotype in the NAFLD spectrum \[[@CR82]--[@CR84]\]. Recent animal studies showed that ipragliflozin treatment attenuated liver dysfunction mediated by steatosis and fibrosis in some rodent models of NASH \[[@CR85], [@CR86]\]. Because SGLT2 is not expressed in the liver, such treatment effects may be caused indirectly by amelioration of systemic IR and inflammation. Treatment with a SGLT2 inhibitor therefore has the potential to improve obesity and diabetes-associated metabolic abnormalities in the entire body, suggesting the possibility of an anti-atherosclerotic action.

This study has several limitations. First, the PROTECT study is not a double blind placebo-controlled trial, but rather an open label design. Unexpected bias towards the assessment of outcomes resulting from the physicians' choice of treatment may occur. To avoid this possible bias, there are strict requirements that the participants' background treatment will, in principle and if possible, remain unchanged during the study. In addition, carotid IMT, a key endpoint in the study, will be measured at a central laboratory, and all the data will be managed and statistically analyzed in a blinded fashion. Second, because the duration of the study is 24 months, it is possible the additional anti-diabetic agents administered when glycemic control becomes worse, especially in the control group, may influence outcomes. It is therefore important to take into account that pioglitazone and some other DPP-4 inhibitors may also prevent progression of carotid IMT in patients with T2DM \[[@CR22]--[@CR24]\]. Third, because the investigators who are participating in the PROTECT study are mainly cardiologists, there may be potential variety of treatment or judgement in the management of diabetes. Therefore, the Steering Committee recommends clinical practice will be performed according to the participants' comprehensive conditions based on the treatment guideline in Japan \[[@CR26]\]. Last, patient's renal function, estimated glomerular filtration rate (eGFR), is not included as an allocation factor, although patients with severe renal dysfunction (eGFR \< 45 ml/min/1.73 m^2^) or receiving dialysis are excluded. The patient's kidney function is one of major determinants of urinary glucose excretion by SGLT2 inhibitor treatment. Previous studies reported that urinary glucose excretion in patients with lower levels of eGFR was actually decreased, and improvement of glycemic control was lower than patients without impairment of renal function \[[@CR87], [@CR88]\]. However, there were SGLT2 inhibitor-induced reductions in body weight and blood pressure independently of patient's renal function \[[@CR89]\]. Thus, we have speculated that anti-atherosclerotic effect may be, in part, caused by ipragliflozin independently of glycemic control and renal function at baseline.

In summary, the PROTECT study is the first to evaluate the effect of ipragliflozin on carotid IMT in patients with T2DM. Clear evidence of the therapeutic effects of SGLT2 inhibitors on atherosclerosis is currently lacking in clinical settings. Given the multi-factorial effects of SGLT2 inhibitors independent of glycemic control, it is not unexpected that ipragliflozin is able to exert a protective action against the atherosclerotic process. This study has the potential to provide new knowledge on effective treatment to prevent atherogenic complications in patients with T2DM.
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